Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia

Leukemia

Volumn 26, Issue 3, 2012, Pages 433-442

  Lengfelder, E ^a   Hofmann, W K ^a   Nowak, D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

acute promyelocytic leukemia; adverse effects; arsenic trioxide; frontline therapy; pharmacologic profile; relapse

Indexed keywords

ARSENIC TRIOXIDE; RETINOIC ACID;

BLEEDING; BLOOD CLOTTING DISORDER; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LIVER TOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84857994331     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.245     Document Type: Review

References (98)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR et al. Proposals for the classification of acute leukaemias. Br J Haematol 1976; 33: 451-458.
2. Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty V et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 1991; 66: 663-674. (Pubitemid 121001702)
3. Chen SJ, Zelent A, Tong JH, Yu HQ, Derré J, Berger R et al. Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J Clin Invest 1993; 91: 2260-2267. (Pubitemid 23141503)
4. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 543-553.
5. Huang M, Ye Y, Chen S, Chai S, Lu JX, Lin Z et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572.
6. Grigniani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M et al. The acute promyelocytic leukemia-specific PML-RARA fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993; 74: 423-431. (Pubitemid 23244608)
7. Sanz M, Grimwade D, Tallman M, Lowenberg B, Fenaux P, Estey E et al. Guidelines on the management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113: 1875-1891.
8. Lengfelder E, Saussele S, Weisser A, Büchner T, Hehlmann R. Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 2005; 56: 261-274. (Pubitemid 41565553)
9. Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M et al. Management of acute promyelocytic leukemia relapse in the ATRA era. Haematologica 1998; 83: 714-717. (Pubitemid 28492153)
10. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000; 14: 1006-1013. (Pubitemid 30389504)
11. Sanz MA, Labopin M, Gorin NC, de la Rubia J, Arcese W, Meloni G et al. Hemotopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2007; 39: 461-469. (Pubitemid 46605204)
12. Doyle AC. Notes of a case of leukocythaemia. Lancet 1882; 119: 490.
13. Forkner CE, Scott TF. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931; 97: 3-5.
14. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostam S, Jahani M, Hosseini R et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134. (Pubitemid 43033852)
15. Mathews V, George B, Kavitha M, Lakshmi KM, Viswabandya A, Bajel A et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627-2632.
16. Miller Jr WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903. (Pubitemid 34792653)
17. Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011; 117: 5795-5802.
18. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-3353. (Pubitemid 27229821)
19. Zhu J, Koken MH, Quignon F, Chelbi-Alix M, Degos L, Wang ZY et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997; 94: 3978-3983. (Pubitemid 27180484)
20. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-1348. (Pubitemid 28509343)
21. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001; 108: 1541-1547. (Pubitemid 33091992)
22. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96: 1525-1530.
23. Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA critical for the lack of responsiveness to arsenic trioxide treatment. Blood 2011; 118: 1600-1609; e-pub ahead of print 25 May 2001; doi:10.1182/ Blood-2011-01-329433.
24. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
25. Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K et al. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 2007; 59: 485-493. (Pubitemid 46122327)
26. Westervelt P, Brown A, Adkins DR, Khoury A, Curtin P, Hurd D et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-271.
27. Wang Z, Zhou J, Lu X, Gong Z, Le XC. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004; 17: 95-103. (Pubitemid 38134064)
28. Sweeney J, Takimoto C, Wood L, Porter JM, Tracewell WG, Darwish M et al. A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemother Pharmacol 2010; 66: 345-356.
29. Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic entered the cerebrospinal fluid during oral arsenic trioxide treatment of meningeal relapse of acute promyelocytic leukemia. Blood 2006; 107: 3012-3013.
30. Helwig A, Klemm M, Schüttig R, Röllig C, Wassilew N, Ehninger G et al. Arsenic-induced APL differentiation in cerebrospinal fluid. Leuk Res 2007; 31: 703-705. (Pubitemid 46559993)
31. Knipp S, Gattermann N, Schapira M, Käferstein H, Germing U. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 2007; 31: 1585-1587. (Pubitemid 47632792)
32. Au WY, Tam S, Fong BM, Kwong YL. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood 2008; 112: 3587-3590.
33. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002; 117: 130-132. (Pubitemid 34304431)
34. Jing Y, Wang L, Xia L, Chen G, Chen Z, Miller WH et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264-269. (Pubitemid 32061269)
35. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335. (Pubitemid 38481160)
36. Giannì M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998; 91: 4300-4310. (Pubitemid 28261995)
37. Leung J, Pang A, Yuen WH, Kwong YL, Tse EW. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemic cells. Blood 2007; 109: 740-746. (Pubitemid 46105976)
38. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci USA 2005; 102: 7653-7658.
39. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111. (Pubitemid 29430427)
40. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277. (Pubitemid 29019412)
41. Bachleitner-Hofmann T, Gisslinger B, Grumbeck E, Gisslinger H. Arsenic trioxide and ascorbic acid: synergy with potential implications for the treatment of acute myeloid leukaemia? Br J Haematol 2001; 112: 783-786. (Pubitemid 32222853)
42. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-1516. (Pubitemid 32183782)
43. Zhang P, Wang S, Hu L, Qui F, yang H, Xiao Y et al. Seven years'summary report on the treatment of acute promyelocytic leukemia with arsenic trioxideFan analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi 2000; 21: 67-70.
44. Soignet SL, Frankel SR, Douer D, Tallman M, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860. (Pubitemid 32880064)
45. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315-3324. (Pubitemid 29536124)
46. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM et al. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15: 735-741. (Pubitemid 32492696)
47. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-279. (Pubitemid 32210296)
48. Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C et al. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation. Haematologica 2002; 87: 485-489. (Pubitemid 34533273)
49. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617-622. (Pubitemid 34449742)
50. Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the MD Anderson experience. Cancer 2003; 97: 2218-2224. (Pubitemid 36444063)
51. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003; 21: 2326-2334. (Pubitemid 46621871)
52. Carmosino I, Latagliata R, Avvisati G, Breccia M, Finalezzi E, Lo-Coco F et al. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia. Haematologica 2004; 89: 615-617. (Pubitemid 38691254)
53. Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005; 82: 224-229. (Pubitemid 41552328)
54. Thomas X, Pigneux A, Raffoux E, Huguet F, Caillot D, Fenaux P. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia. Haematologica 2006; 91: 996-997. (Pubitemid 44023163)
55. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SA et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007; 109: 1355-1359. (Pubitemid 46466562)
56. Alimoghaddam K, Ghavamzadeh A, Jahani M, Mousavi A, Iravani M, Rostami S et al. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran. Arch Iran Med 2011; 14: 167-169.
57. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396-2410. (Pubitemid 46218734)
58. Douer D, Hu W, Giralt S, Lill M, DiPersio J. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003; 8: 132-140. (Pubitemid 36428279)
59. Breccia M, Cicconi L, Minotti C, Latagliata R, Gianni L, Lo-Coco F. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia. Haematologica 2011; e-pub ahead of print 9 June 2011; doi:10.3324/haematol. 2011.045500.
60. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009; 11: 1479-1484.
61. Au W, Lie A, Chim C, Liang R, Ma SK, Chan CH et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003; 14: 752-757. (Pubitemid 36621776)
62. Grigg A, Kimber R, Szer J. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation. Leukemia 2003; 17: 1916-1917.
63. De Botton S, Sanz MA, Chevret S, Dombret H, Martin G, Thomas X et al. Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia 2006; 20: 35-41.
64. Specchia G, Lo Coco F, Vignetti M, Avvisati G, Fazi P, Albano F et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol 2001; 19: 4023-4028. (Pubitemid 32976688)
65. Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S et al. CNS relapse in acute promyeloctyic leukemia. J Clin Oncol 2010; 28: 409-411.
66. Tsimberidou AM, Estey E, Whitman GJ, Dryden M, Ratnam S, Pierce S et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991-994. (Pubitemid 38953655)
67. Kai T, Kimura H, Shiga Y, Ogawa K, Sato H, Maruyama Y. Recurrent extramedullary relapse of acute promyelocytic leukemia after allogeneic stem cell transplantation: successful treatment by arsenic trioxide in combination with local radiotherapy. Int J Hematol 2006; 83: 337-340. (Pubitemid 43807579)
68. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469-3473.
69. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27: 504-510.
70. Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011; 29: 2753-2757.
71. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: longterm follow-up data. J Clin Oncol 2010; 28: 3866-3871.
72. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2009; 106: 3342-3347.
73. Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010; 116: 3751-3757.
74. Gore SD, Gojo I, Sekeres MA, Morris L, Devetten M, Jamieson K et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010; 28: 1047-1053.
75. Ades L, Raffoux E, Chevret S, Pigneux A, Thomas X, Bordessoule D et al. Arsenic trioxide (ATO) in the consolidation treatment of newly diagnosed APLFfirst interim analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 505.
76. Adès L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111: 1078-1084. (Pubitemid 351213385)
77. Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S et al. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia 2009; 23: 2248-2258.
78. Sanz MA, Montesinos P, Rayón C, Holowieckia A, de la Serna J, Milone G et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010; 115: 5137-5146.
79. Lo-Coco F, Avvisati G, Vignetti M, Breccia M, Gallo E, Rambaldi A et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116: 3171-3179.
80. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296.
81. Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA et al. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol 2000; 18: 2620-2625. (Pubitemid 30432530)
82. Arnould C, Philippe C, Bourdon V, Grégoire MJ, Berger R, Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia. Hum Mol Genet 1999; 8: 1741-1749. (Pubitemid 29423884)
83. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor a to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat Genet 1997; 17: 109-113. (Pubitemid 27377543)
84. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin- retinoic acid receptor fusion. Blood 1996; 87: 882-886. (Pubitemid 26043517)
85. Kondo T, Mori A, Darmanin S, Hashino S, Tanaka J, Asaka M. The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia. Haematologica 2008; 93: 1414-1416.
86. Chen Y, Gu L, Zhou C, Wu X, Gao J, Li Q et al. Relapsed APL patient with variant NPM-RARalpha fusion responded to arsenic trioxide-based therapy and achieved long-term survival. Int J Hematol 2010; 91: 708-710.
87. Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A et al. Retinoic acid, but not arsenic trioxide, degrades the PLZF/ RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 1999; 18: 1113-1118. (Pubitemid 29086289)
88. Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood 2010; 115: 1697-1702.
89. Sham RL, Tallman MS. Treatment of acute promyelocytic leukemia in the very elderly: case report and review of the literature. Leuk Res 2004; 28: 1347-1350. (Pubitemid 39314415)
90. Lo-Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229. (Pubitemid 29467668)
91. Lo-Coco F, Romano A, Mengarelli A. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17: 1930-1933. (Pubitemid 37322120)
92. Kohno A, Morishita Y, Iida H, Yanada M, Uchida T, Hamaguchi M et al. Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group. Int J Hematol 2008; 87: 210-216.
93. Lengfelder E, Lo-Coco F, Montesinos P, Grimwade D, Ades L, Kishore B et al. Treatment of molecular and clinical relapse of acute promyelocytic leukemia (APL) with arsenic trioxide: results of the European Registry of Relapsed APL. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 15.
94. Grimwade D, Jovanovic JV, Hills RK, Nugent EA, Patel J, Flora R et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009; 27: 3650-3658.
95. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011; 25: 1128-1134.
96. Park JH, Panageas KS, Schymura MJ, Qiao B, Jurcic JG, Todd L et al. A population-based study in acute promyelocytic leukemia (APL) suggests a higher early death rate and lower overall survival than commonly reported in clinical trials: data from the surveillance, epidemiology, and end results (SEER) program and the New York state cancer registry in the United States between 1992-2007. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 872.
97. Micol JB, Raffoux E, Boissel N, Lengliné E, Canet E, Leblanc T et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the university hospital Saint-Louis between 2000 and 2010. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 1083.
98. Sanz MA, Lo-Coco F, Martin G, Avvisati G, Rayón C, Barbui T et al. Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1252.